Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Tiger Global’s Chase Coleman Made Out Like A Bandit in LinkedIn

Chase Coleman’s Tiger Global disclosed a 4.2% activist stake in LinkedIn (LNKD) on Friday. Tiger Global purchased 300 K shares of LinkedIn at the IPO price of $45 per share. However, they made the following purchases weeks before the IPO:

Chase Coleman Tiger Global Management

1. 10,000 shares of Issuer’s common stock for $34.00 per share on March 24, 2011.

2. 12,500 shares of Issuer’s common stock for $30.79 per share on April 15, 2011.

3. 12,500 shares of Issuer’s common stock for $30.79 per share on April 15, 2011.

4. 19,270 shares of Issuer’s common stock for $35.00 per share on April 15, 2011.

5. 7,000 shares of Issuer’s common stock for $35.00 per share on April 15, 2011.

This is still pocket change though. Coleman’s biggest investment isn’t in LinkedIn’s Class A shares which has one vote per share. Coleman’s biggest investment is in LinkedIn’s Class B shares which has 10 votes per share. Coleman has 3.74 Million Class B shares of LinkedIn. Currently Tiger Global has more than $300 Million invested in LNKD. Their original investment in the company is probably less than $100. Last July Coleman paid $21.50 per share for 1 percent of the company. Given LNKD’s current price of $77, it is clear that Chase Coleman made out like a bandit in LinkedIn. He is also an investor in Facebook. He is probably the best performing hedge fund manager in 2010 (among the hedge funds with $1+ Billion in AUM).

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!